Shilpa Medicare Ltd - Stock Valuation and Financial Performance

BSE: 530549 | NSE: SHILPAMED | Pharmaceuticals & Drugs | Small Cap

Shilpa Medicare Share Price

460.50 6.60 1.45%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Shilpa Medicare

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Shilpa Medicare stock performance -

mw4me loader
P/E Ratio (CD):
0.00
Market Cap:
4,004.6 Cr.
52-wk low:
222.4
52-wk high:
465.6

Is Shilpa Medicare Ltd an attractive stock to invest in?

1. Is Shilpa Medicare Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Shilpa Medicare Ltd is a good quality company.

2. Is Shilpa Medicare Ltd undervalued or overvalued?

The key valuation ratios of Shilpa Medicare Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Shilpa Medicare Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Shilpa Medicare Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Shilpa Medicare:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Shilpa Medicare Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 17.1%11.8%15.4%10.8%8%6.8%9.6%5.2%3.3%-0%-
Value Creation
Index
0.2-0.20.1-0.2-0.4-0.5-0.3-0.6-0.8-1.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5716147167797897339089011,1461,0501,123
Sales YoY Gr.-7.4%16.7%8.8%1.2%-7%23.8%-0.8%27.1%-8.3%-
Adj EPS 11.19.414.4131210.717.710.95.9-4.9-0.1
YoY Gr.--15.8%53.8%-10.1%-7.6%-10.6%65.6%-38.4%-46.3%-182.6%-
BVPS (₹) 53.970.982.9123.2133.1146.9163.1181.4209.9205.4206.1
Adj Net
Profit
81.972.211110497.787.31458951-42.1-1
Cash Flow from Ops. 7068.812937.544.914712446.9105226-
Debt/CF from Ops. 1.72.70.76.44.31.33.1186.53.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7%5.9%5%-8.3%
Adj EPS -191.2%-183.5%-164.9%-182.6%
BVPS16%9.1%8%-2.1%
Share Price 8.6% 6.2% 11.5% 101.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
22.815.318.712.89.47.711.46.33.1-2.3-0
Op. Profit
Mgn %
21.320.622.520.819.221.123.619.117.48.418.9
Net Profit
Mgn %
14.211.61512.912.111.515.89.74.4-3.9-0.1
Debt to
Equity
0.30.30.10.20.20.20.30.60.40.5-
Working Cap
Days
135158158193237266230286280308125
Cash Conv.
Cycle
4056598411614112617016418613

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 0.00%

Sales growth has been subdued in last 3 years 4.97%

Sales growth is not so good in last 4 quarters at 1.30%

Latest Financials - Shilpa Medicare Ltd.

Standalone Consolidated
TTM EPS (₹) -1.4 -0.1
TTM Sales (₹ Cr.) 289 1,123
BVPS (₹.) 245.9 206.1
Reserves (₹ Cr.) 2,126 1,781
P/BV 1.88 2.24
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 222.40 / 465.60
All Time Low / High (₹) 0.39 / 786.75
Market Cap (₹ Cr.) 4,005
Equity (₹ Cr.) 8.7
Face Value (₹) 1
Industry PE 48.2

Management X-Ray of Shilpa Medicare:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.810.810.810.810.811.3812.9012.9090.4190.41
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Shilpa Medicare

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales5716147167797897339089011,1461,050
Operating Expenses 455487556618638579693729948962
Manufacturing Costs455667798995118132177171
Material Costs313323366372356257278271383416
Employee Cost 688290128149176197235264287
Other Costs 3026333944511019212487
Operating Profit 11612616016215115421517219788
Operating Profit Margin (%) 20.3%20.6%22.3%20.7%19.2%21.0%23.6%19.1%17.2%8.4%
Other Income 971129331622402131
Interest 4443345224159
Depreciation 23212331374244548095
Exceptional Items -30-2-502006190
Profit Before Tax 95108140146137136188195102-38
Tax 203536423426334942-7
Profit After Tax 757310510410311015514661-31
PAT Margin (%) 13.2%11.8%14.6%13.4%13.0%14.9%17.0%16.2%5.3%-2.9%
Adjusted EPS (₹)10.39.614.113.412.913.819.218.17.0-3.7
Dividend Payout Ratio (%)5%6%4%4%5%7%6%6%16%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 3965476399871,0851,1981,3291,4791,8221,783
Share Capital 7888888899
Reserves 3895396329791,0771,1891,3211,4711,8141,775
Minority Interest10142-3-5-8-8-11-11-9
Debt9816174235166168330718557633
Long Term Debt6710201436881165474354289
Short Term Debt305874929887165243203344
Trade Payables9376106112104819377146144
Others Liabilities 81107109141149172245371362351
Total Liabilities 6789059311,4721,4991,6101,9892,6322,8752,902

Fixed Assets

Gross Block4484765827057938539861,4211,7271,847
Accumulated Depreciation154160189213259295336311385478
Net Fixed Assets2943163934925345586501,1111,3421,368
CWIP 11122292141210429666541506655
Investments 106694253140210213443
Inventories123131134190189188226333355320
Trade Receivables6881125171220204247234386324
Cash Equivalents 918111007495451243422
Others Assets627181126132135144269218170
Total Assets 6789059311,4721,4991,6101,9892,6322,8752,902

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 7069129374514712447105226
PBT 95108140146137136188195102-38
Adjustment 202621171928426109148
Changes in Working Capital -23-40-3-93-7019-63-106-72149
Tax Paid -22-25-30-34-41-36-42-48-34-32
Cash Flow From Investing Activity -49-195-109-262-9-196-290-404-285-278
Capex -104-145-114-116-137-297-345-349-331-271
Net Investments 54-554-149125158-10514-9
Others 25134-5765-60312
Cash Flow From Financing Activity -28136-20313-61101764368346
Net Proceeds from Shares 081017200002970
Net Proceeds from Borrowing -7300128-56-6882381-121-27
Interest Paid -4-4-4-3-3-4-4-22-41-58
Dividend Paid -4-5-11-5-70-170-9-10
Others -1433-52158211578-42141
Net Cash Flow -710088-25-391079-98-7
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)20.9815.417.6612.859.939.5912.2310.413.67-1.71
ROCE (%)20.4817.919.6915.2811.1310.4512.3810.735.940.8
Asset Turnover Ratio0.940.780.790.650.530.470.50.390.420.36
PAT to CFO Conversion(x)0.930.951.230.360.441.340.80.321.72N/A
Working Capital Days
Receivable Days3544526990106919799124
Inventory Days62756775879483113110117
Payable Days849591107111131114114106127

Shilpa Medicare Ltd Stock News

Shilpa Medicare Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Shilpa Medicare on 28-Mar-2024 16:01 is ₹460.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Shilpa Medicare stood at ₹4,004.6.
The latest P/E ratio of Shilpa Medicare as of 28-Mar-2024 16:01 is 0.00.
The latest P/B ratio of Shilpa Medicare as of 28-Mar-2024 16:01 is 1.88.
The 52-week high of Shilpa Medicare is ₹465.6 and the 52-week low is ₹222.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Shilpa Medicare is ₹288.8 ( Cr.) .

About Shilpa Medicare Ltd

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.  

The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh.  Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.

Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.

Product range of the company includes:

Oncology AP's

  • Anastrozole 
  • Bicalutamide 
  • Carboplatin 
  • Gemcitabine HCI
  •  Irinotecan HCl Trihydrate
  • Oxaliplatin 
  • Temozolomide 
  • Cisplatin 
  • 5-Fluoro
  • Bortezomib 
  • Capecitabine 
  • Decarbazine 
  • Docetaxel 
  • Gefitinib 
  • Hydroxy urea 
  • Imatinib Mesylate 
  • Lenalidomide 
  • Letrozole
  • Methotrexate 
  • Thalidomide 
  • Topotecan HCl
  • Zoledronic acid 

General APIs

  • Ambroxol HCl 
  • Ticlopidine HCl 
  • Buflomedil HCl 
  • Nifedipine 
  • Lamivudine 
  • Sildenafil Citrate 
  • Terfenadine 
  • Acebrophylline 
  • Phenylephrine HCl 
  • Ursodeoxycholic acid 

PRODUCTS UNDER DEVELOPMENT (Oncology)

  •  Bendamustine Cladribine
  •  Decitabine Disodium Pamidronate
  •  Epirubicin Exemustane
  •  Fludarabine Phosphate  Idarubicine
  •  Paclitaxel  Pemetrexed
  •  Lomustine  Methotrexate
  •  Pamidronic acid  Tandutinib 

NUTRITIONAL SUPPLEMENTS 

  • Chromium picolinate  Chromium polynicotinate   

DRUG INTERMEDIATES

  • Trans-4-amino cyclohexanol
  • 2-Amino-3,5-dibromobenzaldehyde
  • 1,3,5-Trimethoxy Benzene 
  • 1,3,5-Tribromo Benzene
  • 7-ethyl camptothecin 
  • 7-ethyl-10-hydroxy camptothecin

Awards & Achievements:

  • Karnataka State Govt. 'Best Enterpreneur Award'.
  • Govt. of India 'Best Enterpreneur Award'.
  • ‘Star Export House’ Status from Ministry of Commerce and Industry, Govt. of India
  • 'cGMP' Certificates from W.H.O. for 20 API's
  • 'Best Export Award' from Visvesvaraya Industrial Trade Centre, Bangalore, Govt. of Karnataka,  INDIA
  • 'Outstanding Industrial Award' from Indian Junior Chamber.
  • 'Registration with 'Russian Health Authority' for Ambroxol HCl
  • 'Certificate of Suitability' received from EDQM for Ambroxol HCl (R0-CEP 2004-201-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Ticlopidine HCl (R0-CEP 2005-004-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Carboplatin (R0-CEP 2006-212-Rev 00)
  • Patent application on Irinotecan HCl Trihydrate 'An improved process for the preparation of Irinotecan HCl Trihydrate' published as WO2006016203 on date 2006-02-16
  • Patent file for Gemcitabine HCl and Anastrozole manufacturing process.
  • Filed ASMF/EDMF of Gemcitabine HCl over 21 EU countries
  • Filed ASMF/EDMF of Irinotecan HCl Trihydrate HCl over 27 EU countries
  • Filed ASMF/EDMF of Oxaliplatin HCl over 11 EU countries
  • 'Best District Export Award' received from FKCCI, Bangalore on 16.06.2007
  • Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl
  • COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)
  • COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)
  • 'Best District Export Award' received from FKCCI, Bangalore on 20.06.2008.
  • COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00)
  • 2010 - Shilpa Medicare Limited was granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride
  • 2012 - Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.